Sign In
Buy ABUS
$4.35
+0.0900 (+2.11%)
At Close: Jun 03, 2026
Moderna Lost a Patent Case and the Stock Is Slipping
07:31pm, Friday, 24'th Jul 2020
What the decision handed down Thursday by the Patent Trial and Appeal Board could mean for Moderna (ticker: MRNA) isn’t yet clear, but the stock fell 9.5% on Thursday, and was down another 5% Friday
Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications
04:57pm, Friday, 24'th Jul 2020
The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.
How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program
03:25pm, Friday, 24'th Jul 2020
Moderna Inc (NASDAQ: MRNA) shares came under significant selling pressure Thursday afternoon following an adverse patent ruling, and the stock is adding to the losses in Friday's session. Moderna Lose
Moderna's stock falls the day after 'disappointing' patent ruling
12:59pm, Friday, 24'th Jul 2020
Shares of Moderna Inc. were down 4.7% in premarket trading on Friday, the day after the U.S. Patent and Trademark Office ruled in favor of Arbutus Biopharma Corp. in a patent dispute between the com
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
11:15am, Friday, 24'th Jul 2020
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) * Abbott Laboratories (NYSE: ABT) * ABIOMED, Inc. (NASDAQ: ABMD) * Acceleron Pharma Inc (NASDAQ: XLRN) * Aerpio Pharmaceuticals Inc (NA
Moderna loses challenge to Arbutus patent on vaccine technology
04:38am, Friday, 24'th Jul 2020
An administrative court run by the U.S. Patent and Trademark Office rejected arguments by Moderna that an Arbutus patent known as the '069 patent should be revoked because it described obvious concept
Moderna Faces Hurdle With Coronavirus Vaccine As Court Refuses To Invalidate Arbutus Patent
04:02am, Friday, 24'th Jul 2020
Moderna Inc (NASDAQ: MRNA) has lost the bid to invalidate a key patent related to the development of several of its next-generation vaccines, including one meant for coronavirus, to Arbutus Biopharma
Moderna Dives On Patent Battle That Could Jeopardize Coronavirus Vaccine
09:39pm, Thursday, 23'rd Jul 2020
Moderna stock tumbled late Thursday after the biotech lost a patent battle that could jeopardize the financial future of its coronavirus vaccine. Moderna denies a threat to vaccine profits.
How R&D Expenses Can Help You Pick Outperforming Stocks
12:13pm, Thursday, 02'nd Jul 2020
A simple two-rule screen can help you pick R&D-intensive stocks primed to outperform. The differences between R&D expenditures and capital expenditures vary bet
Is Arbutus Biopharma Corp (ABUS) A Good Stock To Buy?
12:18am, Tuesday, 16'th Jun 2020
In this article we will take a look at whether hedge funds think Arbutus Biopharma Corp (NASDAQ:ABUS) is a good investment right now. We check hedge fund and billionaire investor sentiment before delv
Arbutus to Present at Jefferies Virtual Healthcare Conference
12:00pm, Wednesday, 27'th May 2020
WARMINSTER, Pa., May 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
05:18pm, Wednesday, 20'th May 2020
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
P/E Ratio Insights for Arbutus Biopharma
03:11pm, Tuesday, 19'th May 2020
In the current session, Arbutus Biopharma Inc. (NASDAQ: ABUS) is trading at $2.43, after a 29.79% increase. Over the past month, the stock increased by 103.10%, and in the past year, by 16.12%. With p
Arbutus Biopharma Corporation (ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today reports positive follow-u
Forecast: Analysts Think Arbutus Biopharma Corporation's (NASDAQ:ABUS) Business Prospects Have Improved Drastically
10:05am, Monday, 18'th May 2020
Celebrations may be in order for Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders, with the analysts...
